Top

Published in:

01-04-2008 | Review

Advances in the diagnosis and immunotherapy for ocular inflammatory disease

Authors: Steven Yeh, Lisa J. Faia, Robert B. Nussenblatt

Published in: Seminars in Immunopathology | Issue 2/2008

Abstract

Significant advances in the diagnosis and therapy for uveitis have been made to improve the quality of care for patients with ocular inflammatory diseases. While traditional ophthalmic examination techniques, fluorescein angiography, and optical coherence tomography continue to play a major role in the evaluation of patients with uveitis, the advent of spectral domain optical coherence tomography and fundus autofluorescence into clinical practice provides additional information about disease processes. Polymerase chain reaction and cytokine diagnostics have also continued to play a greater role in the evaluation of patients with inflammatory diseases. The biologic agents, a group of medications that targets cytokines and other soluble mediators of inflammation, have demonstrated promise in targeted immunotherapy for specific uveitic entities. Their ophthalmic indications have continued to expand, improving the therapeutic armentarium of uveitis specialists.

Nussenblatt RB, Whitcup SC (2004) Uveitis: Fundamentals and clinical practice, 3rd edn. Elsevier, Philadelphia

Jabs DA, Akpek EK (2005) Immunosuppression for posterior uveitis. Retina 25(1):1–18PubMed

Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492–513PubMed

Lim L, Suhler EB, Smith JR (2006) Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 34(4):365–374PubMed

Yeh S, Nussenblatt RB, Levy-Clarke GA (2007) Exp Rev Clin Immunol 3(5):781–796

Nussenblatt RB, Caspi RR, Dinning WJ, Palestine AG, Hiestand P, Borel J (1986) A comparison of the effectiveness of cyclosporine A, D, and G in the treatment of experimental autoimmune uveitis in rats. J Immunopharmacol 8(3):427–435PubMed

Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA, Lando Z, Nussenblatt RB (1988) A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 140(5):1490–1495PubMed

Nussenblatt RB, Ferris F 3rd (2007) Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol 144(4):618–626PubMed

Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18(12):1450–1452PubMed

10.

Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308(5720):385–389PubMed

11.

Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308(5720):421–424PubMed

12.

Dastgheib K, Green WR (1994) Granulomatous reaction to Bruch’s membrane in age-related macular degeneration. Arch Ophthalmol 112(6):813–818PubMed

13.

Sarks JP, Sarks SH, Killingsworth MC (1997) Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye 11(Pt 4):515–522PubMed

14.

Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516PubMed

15.

Moorthy RS, Valluri S, Jampol LM (1998) Drug-induced uveitis. Surv Ophthalmol 42(6):557–570PubMed

16.

Hopkins J, Walsh A, Chakravarthy U (2006) Fundus autofluorescence in age-related macular degeneration: an epiphenomenon? Invest Ophthalmol Vis Sci 47(6):2269–2271PubMed

17.

Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995) In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36(3):718–729PubMed

18.

Delori FC, Goger DG, Dorey CK (2001) Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci 42(8):1855–1866PubMed

19.

Spaide RF (2003) Fundus autofluorescence and age-related macular degeneration. Ophthalmology 110(2):392–399PubMed

20.

Spaide RF, Klancnik JM Jr (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112(5):825–33PubMed

21.

Yannuzzi LA, Ober MD, Slakter JS, Spaide RF, Fisher YL, Flower RW, Rosen R (2004) Ophthalmic fundus imaging: today and beyond. Am J Ophthalmol 137(3):511–524PubMed

22.

Souka AA, Hillenkamp J, Gora F, Gabel VP, Framme C (2006) Correlation between optical coherence tomography and autofluorescence in acute posterior multifocal placoid pigment epitheliopathy. Graefes Arch Clin Exp Ophthalmol 244(10):1219–1223PubMed

23.

Bellmann C, Holz FG, Breitbart A, Völcker HE (1999) Bilateral acute syphilitic posterior placoid chorioretinopathy–angiographic and autofluorescence characteristics. Ophthalmologe 96(8):522–528PubMed

24.

Spaide RF (2004) Collateral damage in acute zonal occult outer retinopathy. Am J Ophthalmol 138(5):887–889PubMed

25.

Popović P, Jarc-Vidmar M, Hawlina M (2005) Abnormal fundus autofluorescence in relation to retinal function in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 243(10):1018–1027PubMed

26.

Ergun E, Hermann B, Wirtitsch M, Unterhuber A, Ko TH, Sattmann H, Scholda C, Fujimoto JG, Stur M, Drexler W (2005) Assessment of central visual function in Stargardt’s disease/fundus flavimaculatus with ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci 46(1):310–316PubMed

27.

Spaide RF, Noble K, Morgan A, Freund KB (2006) Vitelliform macular dystrophy. Ophthalmology 113(8):1392–1400PubMed

28.

Sawa M, Ober MD, Freund KB, Spaide RF (2006) Fundus autofluorescence in patients with pseudoxanthoma elasticum. Ophthalmology 113(5):814–820 e2PubMed

29.

Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA et al (1991) Optical coherence tomography. Science 254(5035):1178–1181 (Nov 22)PubMed

30.

Gallagher MJ, Yilmaz T, Cervantes-Castañeda RA, Foster CS (2007) The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol 91(12):1680–1685PubMed

31.

Markomichelakis NN, Halkiadakis I, Pantelia E, Peponis V, Patelis A, Theodossiadis P, Theodossiadis G (2004) Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111(5):946–953PubMed

32.

Catier A, Tadayoni R, Paques M, Erginay A, Haouchine B, Gaudric A, Massin P (2005) Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 140(2):200–206PubMed

33.

Kiss CG, Barisani-Asenbauer T, Maca S, Richter-Mueksch S, Radner W (2006) Reading performance of patients with uveitis-associated cystoid macular edema. Am J Ophthalmol 142(4):620–624PubMed

34.

Sivaprasad S, Ikeji F, Xing W, Lightman S (2007) Tomographic assessment of therapeutic response to uveitic macular oedema. Clin Exp Ophthalmol 35(8):719–723

35.

Srinivasan VJ, Wojtkowski M, Witkin AJ, Duker JS, Ko TH, Carvalho M, Schuman JS, Kowalczyk A, Fujimoto JG (2006) High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 113(11):2054 e1–14PubMed

36.

Forster DJ, Cano MR, Green RL, Rao NA (1990) Echographic features of the Vogt–Koyanagi–Harada syndrome. Arch Ophthalmol 108(10):1421–1426PubMed

37.

McCluskey PJ, Watson PG, Lightman S, Haybittle J, Restori M, Branley M (1999) Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 106(12):2380–2386PubMed

38.

Greiner KH, Kilmartin DJ, Forrester JV, Atta HR (2002) Grading of pars planitis by ultrasound biomicroscopy–echographic and clinical study. Eur J Ultrasound 15(3):139–144PubMed

39.

Häring G, Nölle B, Wiechens B (1998) Ultrasound biomicroscopic imaging in intermediate uveitis. Br J Ophthalmol 82(6):625–629PubMed

40.

Roters S, Szurman P, Engels BF, Bartz-Schmidt KU, Krieglstein GK (2002) Ultrasound biomicroscopy in chronic ocular hypotony: its impact on diagnosis and management. Retina 22(5):581–588PubMed

41.

Tran VT, LeHoang P, Herbort CP (2001) Value of high-frequency ultrasound biomicroscopy in uveitis. Eye 15(Pt 1):23–30PubMed

42.

Rosenbaum JT, Wernick R (1990) The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol 108(9):1291–1293PubMed

43.

Van Gelder RN (2001) Applications of the polymerase chain reaction to diagnosis of ophthalmic disease. Surv Ophthalmol 46(3):248–258PubMed

44.

Van Gelder RN (2003) Cme review: polymerase chain reaction diagnostics for posterior segment disease. Retina 23(4):445–452PubMed

45.

Doornenbal P, Seerp Baarsma G, Quint WG, Kijlstra A, Rothbarth PH, Niesters HG (1996) Diagnostic assays in cytomegalovirus retinitis: detection of herpesvirus by simultaneous application of the polymerase chain reaction and local antibody analysis on ocular fluid. Br J Ophthalmol 80(3):235–240PubMed

46.

Tran TH, Rozenberg F, Cassoux N, Rao NA, LeHoang P, Bodaghi B (2003) Polymerase chain reaction analysis of aqueous humour samples in necrotising retinitis. Br J Ophthalmol 87(1):79–83PubMed

47.

Knox CM, Chandler D, Short GA, Margolis TP (1998) Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis. Use in diagnostic dilemmas. Ophthalmology 105(1):37–44PubMed

48.

Chiquet C, Bodaghi B, Mouqin C, Najioullah F (2006) Acute retinal necrosis diagnosed in a child with chronic panuveitis. Graefes Arch Clin Exp Ophthalmol 244(9):1206–1208PubMed

49.

Yin PD, Kurup SK, Fischer SH, Rhee HH, Byrnes GA, Levy-Clarke GA, Buggage RR, Nussenblatt RB, Mican JM, Wright ME (2007) Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol 38(3):254–259PubMed

50.

Asano S, Yoshikawa T, Kimura H, Enomoto Y, Ohashi M, Terasaki H, Nishiyama Y (2004) Monitoring herpesvirus DNA in three cases of acute retinal necrosis by real-time PCR. J Clin Virol 29(3):206–209PubMed

51.

Gupta V, Gupta A, Arora S, Bambery P, Dogra MR, Agarwal A (2003) Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology 110(9):1744–1749PubMed

52.

Gupta A, Gupta V, Arora S, Dogra MR, Bambery P (2001) PCR-positive tubercular retinal vasculitis: clinical characteristics and management. Retina 21(5):435–444PubMed

53.

Arora SK, Gupta V, Gupta A, Bambery P, Kapoor GS, Sehgal S (1999) Diagnostic efficacy of polymerase chain reaction in granulomatous uveitis. Tuber Lung Dis 79(4):229–233PubMed

54.

Rao NA, Saraswathy S, Smith RE (2006) Tuberculous uveitis: distribution of Mycobacterium tuberculosis in the retinal pigment epithelium. Arch Ophthalmol 124(12):1777–1779PubMed

55.

Ortega-Larrocea G, Bobadilla-del-Valle M, Ponce-de-León A, Sifuentes-Osornio J (2003) Nested polymerase chain reaction for Mycobacterium tuberculosis DNA detection in aqueous. and vitreous of patients with uveitis. Arch Med Res 34(2):116–119PubMed

56.

Aouizerate F, Cazenave J, Poirier L, Verin P, Cheyrou A, Begueret J, Lagoutte F (1993) Detection of Toxoplasma gondii in aqueous humour by the polymerase chain reaction. Br J Ophthalmol 77(2):107–109PubMed

57.

De Groot-Mijnes JD, Rothova A, Van Loon AM, Schuller M, Ten Dam-Van Loon NH, De Boer JH, Schuurman R, Weersink AJ (2006) Polymerase chain reaction and Goldmann–Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J Ophthalmol 141(2):313–318PubMed

58.

Westeneng AC, Rothova A, de Boer JH, de Groot-Mijnes JD (2007) Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann–Witmer coefficient in aqueous analysis. Am J Ophthalmol 144(5):781–785PubMed

59.

Curnow SJ, Murray PI (2006) Inflammatory mediators of uveitis: cytokines and chemokines. Curr Opin Ophthalmol 17(6):532–537PubMed

60.

Chan CC, Whitcup SM, Solomon D, Nussenblatt RB (1995) Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. Am J Ophthalmol 120(5):671–673PubMed

61.

Chan CC (2003) Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc 101:275–292PubMed

62.

Buggage RR, Whitcup SM, Nussenblatt RB, Chan CC (1999) Using interleukin 10 to interleukin 6 ratio to distinguish primary intraocular lymphoma and uveitis. Invest Ophthalmol Vis Sci 40(10):2462–2463PubMed

63.

Ahn JK, Yu HG, Chung H, Park YG (2006) Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol 142(3):429–434PubMed

64.

Norose K, Yano A, Wang XC, Tokushima T, Umihira J, Seki A, Nohara M, Segawa K (1994) Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt–Koyanagi–Harada disease. Invest Ophthalmol Vis Sci 35(1):33–39PubMed

65.

Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S (2001) Cytokine production and helper T cell subsets in Vogt–Koyanagi–Harada’s disease. Curr Eye Res 22(4):312–318PubMed

66.

Takase H, Futagami Y, Yoshida T, Kamoi K, Sugita S, Imai Y, Mochizuki M (2006) Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci 47(4):1557–1561PubMed

67.

Curnow SJ, Falciani F, Durrani OM, Cheung CM, Ross EJ, Wloka K, Rauz S, Wallace GR, Salmon M, Murray PI (2005) Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 46(11):4251–4259PubMed

68.

Ooi KG, Galatowicz G, Towler HM, Lightman SL, Calder VL (2006) Multiplex cytokine detection versus ELISA for aqueous humor: IL-5, IL-10, and IFNgamma profiles in uveitis. Invest Ophthalmol Vis Sci 47(1):272–277PubMed

69.

Deierhoi MH, Kauffman RS, Hudson SL, Barber WH, Curtis JJ, Julian BA, Gaston RS, Laskow DA, Diethelm AG (1993) Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 217(5):476–482PubMed

70.

Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M (2007) Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 91(2):180–184PubMed

71.

Choudhary A, Harding SP, Bucknall RC, Pearce IA (2006) Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther 22(3):168–175PubMed

72.

Vianna RN, Ozdal PC, Deschênes J, Burnier MN Jr (2006) Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can J Ophthalmol 41(2):183–189PubMed

73.

Akpek EK, Baltatzis S, Yang J, Foster CS (2001) Long-term immunosuppressive treatment of serpiginous choroiditis. Ocul Immunol Inflamm 9(3):153–167PubMed

74.

Kim SJ, Yu HG (2007) The use of low-dose azathioprine in patients with Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm 15(5):381–387PubMed

75.

Berker N, Ozdamar Y, Soykan E, Ozdal P, Ozkan SS (2007) Vogt–Koyanagi–Harada syndrome in children: report of a case and review of the literature. Ocul Immunol Inflamm 15(4):351–357PubMed

76.

Hakin KN, Pearson RV, Lightman SL (1992) Sympathetic ophthalmia: visual results with modern immunosuppressive therapy. Eye 6(Pt 5):453–455PubMed

77.

Hooper PL, Kaplan HJ (1991) Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology 98(6):944–951PubMed

78.

Kaplan-Messas A, Barkana Y, Avni I, Neumann R (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11(2):131–139PubMed

79.

Samson CM, Waheed N, Baltatzis S, Foster CS (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108(6):1134–1139PubMed

80.

Kim SK, Chan CC, Wallace DJ (2005) Management of primary intraocular lymphoma. Curr Oncol Rep 7(1):74–79PubMed

81.

Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB (1991) Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 112(2):138–146PubMed

82.

Walton RC, Nussenblatt RB, Whitcup SM (1998) Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 105(11):2028–2034PubMed

83.

Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD (2005) Cyclosporine vs. tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123(5):634–641PubMed

84.

Fujino Y, Okumura A, Nussenblatt RB, Gery I, Mochizuki M (1988) Cyclosporine-induced specific unresponsiveness to retinal soluble antigen in experimental autoimmune uveoretinitis. Clin Immunol Immunopathol 46(2):234–248PubMed

85.

Caspi RR, McAllister CG, Gery I, Nussenblatt RB (1988) Differential effects of cyclosporins A and G on functional activation of a T-helper-lymphocyte line mediating experimental autoimmune uveoretinitis. Cell Immunol 113(2):350–360PubMed

86.

Nussenblatt RB, de Smet MD, Rubin B, Freidlin V, Whitcup SM, Davis J, Herman D, Bloom JN, Sran PK, Whitcher S et al (1993) A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol 115(5):583–591PubMed

87.

Hogan AC, McAvoy CE, Dick AD, Lee RW (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114(5):1000–1006PubMed

88.

Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106(4):723–728PubMed

89.

Durrani K, Papaliodis GN, Foster CS (2004) Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 111(5):960–965PubMed

90.

Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH (2002) Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 109(2):370–377PubMed

91.

Valmaggia C, Neuweiler J (2001) Orbital involvement as the first manifestation in classic Wegener’s granulomatosis. Orbit 20(3):231–237PubMed

92.

Florine CW, Dwyer M, Holland EJ (1993) Wegener’s granulomatosis presenting with sclerokeratitis diagnosed by antineutrophil cytoplasmic autoantibodies (ANCA). Surv Ophthalmol 37(5):373–376PubMed

93.

Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS (2002) Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109(8):1506–1513PubMed

94.

Davatchi F, Baygan F, Chams H, Chams C (1984) Cyclophosphamide in the treatment of the ocular manifestations of Behçet’s disease. J Rheumatol 11(3):404–405PubMed

95.

Yang CS, Liu JH (1995) Chlorambucil therapy in sympathetic ophthalmia. Am J Ophthalmol 119(4):482–488PubMed

96.

Tessler HH, Jennings T (1990) High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet’s disease. Br J Ophthalmol 74(6):353–357PubMed

97.

Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO (2001) Short-term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Immunol Inflamm 9(4):219–229PubMed

98.

Hale S, Lightman S (2006) Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33(4):231–237PubMed

99.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932–1939PubMed

100.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594–1602PubMed

101.

Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549PubMed

102.

Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193PubMed

103.

Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E (2002) Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 22(6):227–232PubMed

104.

Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123(7):903–912PubMed

105.

Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford) 46(7):1161–1164

106.

Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A (2005) Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int Ophthalmol 26(3):83–92PubMed

107.

Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gul A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum 52(8):2478–2484PubMed

108.

Sharma SM, Ramanan AV, Riley P, Dick AD (2007) Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: Efficacy in joint and ocular disease. Ann Rheum Dis 66(6):840–841PubMed

109.

Richards JC, Tay-Kearney ML, Murray K, Manners P (2005) Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 33(5):461–468

110.

Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113(2):308–314PubMed

111.

Kahn P, Weiss M, Imundo LF, Levy DM (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113(5):864 e1–2

112.

El-Shabrawi Y, Hermann J (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109(12):2342–2346PubMed

113.

Thomas JW, Pflugfelder SC (2005) Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea 24(6):742–744PubMed

114.

Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D (2004) Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111(2):352–356PubMed

115.

El-Shabrawi Y, Hermann J (2005) Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener’s granulomatosis. Eye 19(9):1017–1018PubMed

116.

Atchia II, Kidd CE, Bell RW (2006) Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol 12(6):291–293PubMed

117.

Cazabon S, Over K, Butcher J (2005) The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye 19(2):222–224 (Feb)PubMed

118.

Mejico LJ, Infliximab-associated retrobulbar optic neuritis (2004) Arch Ophthalmol 122(5):793–794PubMed

119.

Lanthier N, Parc C, Scavennec R, Dhôte R, Brézin AP, Guillevi L (2005) Infliximab in the treatment of posterior uveitis in Behçet’s disease. Long term follow up in four patients. Presse Med 34(13):916–918PubMed

120.

Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M (2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44(2):265–267PubMedCrossRef

121.

Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64(5):699–703PubMed

122.

Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56(5):1433–1439PubMed

123.

Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64(10):1414–1420PubMed

124.

Vazquez-Cobian LB, Flynn T, Lehman TJ (2006) Adalimumab therapy for childhood uveitis. J Pediatr 149(4):572–575PubMed

125.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M (2007) Adalimumab in the therapy of uveitis in childhood. Br J Opthalmol 91(3):319–324

126.

van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM (2007) Adalimumab: a new modality for Behçet’s disease? Ann Rheum Dis 66(4):565–566PubMed

127.

Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye 21(6):824–825PubMed

128.

van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146PubMed

129.

Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65(7):889–894PubMed

130.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681PubMed

131.

Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763–769PubMed

132.

Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272PubMed

133.

Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600PubMed

134.

Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44(8):1008–1011

135.

Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53(1):18–23PubMed

136.

Smith BJ, McMillan VM, Newton JS (2001) Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. J Clin Rheumatol 7(3):175–178PubMed

137.

Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113(12):2317–2323PubMed

138.

Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34(5):1146–1150PubMed

139.

Reddy AR, Backhouse OC (2003) Does etanercept induce uveitis? Br J Ophthalmol 87(7):925PubMed

140.

Taban M, Dupps WJ, Mandell B, Perez VL (2006) Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 14(3):145–150PubMed

141.

Tauber T, Turetz J, Barash J, Avni I, Morad Y (2006) Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 10(1):26–29PubMedCrossRef

142.

Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED (2006) Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 149(6):833–836PubMed

143.

Torun N, Callizo J, Orlic N, Scherer M, Hartmann C, Pleyer U (2005) Serum cytokine receptor levels in noninfectious uveitis. Ophthalmic Res 37(2):112–116PubMed

144.

Martin CM, Lacomba MS, Molina CI, Chamond RR, Galera JM, Estevez EC (2000) Levels of soluble ICAM-1 and soluble IL-2R in the serum and aqueous humor of uveitis patients. Curr Eye Res 20(4):287–292PubMed

145.

Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P, Sran P, Yaffe A, Goldman CK, Waldmann TA, Whitcup SM (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 96(13):7462–7466PubMed

146.

Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21(3):283–93PubMed

147.

Papaliodis GN, Chu D, Foster CS (2003) Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110(4):786–789PubMed

148.

Kiss S, Ahmed M, Letko E, Foster CS (2005) Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 112(6):1066–1071PubMed

149.

Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS (2007) Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 91(10):1341–1344PubMed

150.

Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F, Phase III Daclizumab Study Group (2001) Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72(5):839–845PubMed

151.

Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338(3):161–165PubMed

152.

Thomas PB, Albini T, Giri RK, See RF, Evans M, Rao NA (2005) The effects of atorvastatin in experimental autoimmune uveitis. Br J Ophthalmol 89(3):275–279PubMed

153.

Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, Peng B, Tobe T, Campochiaro PA, Vinores SA (1997) Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res 49(3):268–280PubMed

154.

de Vos AF, Klaren VN, Kijlstra A (1994) Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 35(11):3873–3883PubMed

155.

Lim WK, Fujimoto C, Ursea R, Mahesh SP, Silver P, Chan CC, Gery I, Nussenblatt RB (2005) Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 123(7):957–963PubMed

156.

Benezra D, Maftzir G, Barak V (1997) Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behcet disease. Am J Ophthalmol 123(5):593–598PubMed

157.

Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614–624PubMed

158.

Reiff A (2005) The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 7(6):434–440PubMed

159.

Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91(2):263–264PubMed

160.

Aróstegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, García-Consuegra J, Naranjo A, Ramos E, de Paz P, Rius J, Plaza S, Yagüe J (2007) NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 56(11):3805–3813PubMed

161.

Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L (2007) Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford) 46(6):1042–1043

162.

Carrasco R, Smith JA, Lovell D (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 6(3):137–146PubMed

163.

Flynn JM, Byrd JC (2000) Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12(6):574–581PubMed

164.

Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, Isaacs JD (2000) Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 84(1):107–109PubMed

165.

Isaacs JD, Hale G, Waldmann H, Dick AD, Haynes R, Forrester JV, Watson P, Meyer PA (1995) Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol 79(11):1054–1055PubMed

166.

Klastersky J (2006) Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol 18(4):316–3120PubMed

167.

Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA, CLEAR Multinational Study Group (2006) Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155(1):170–181PubMed

168.

Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W (2005) Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141(1):31–38PubMed

169.

Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, Simpson E (2007) Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 56(2):222–227PubMed

170.

Xu H, Forrester JV, Liversidge J, Crane IJ (2003) Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest Ophthalmol Vis Sci 44(1):226–234PubMed

171.

Whitcup SM, DeBarge LR, Rosen H, Nussenblatt RB, Chan CC (1993) Monoclonal antibody against CD11b/CD18 inhibits endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 34(3):673–681PubMed

172.

Whitcup SM, Hikita N, Shirao M, Miyasaka M, Tamatani T, Mochizuki M, Nussenblatt RB, Chan CC (1995) Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp Eye Res 60(6):597–601PubMed

173.

Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A (2006) A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 213(3):204–214PubMed

174.

Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P (2005) Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112(7):1192–1198PubMed

175.

Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T (2006) Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113(6):1020–1027PubMed

176.

Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125(3):309–317PubMed

Title: Advances in the diagnosis and immunotherapy for ocular inflammatory disease
Authors: Steven Yeh
Lisa J. Faia
Robert B. Nussenblatt
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 2/2008
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-008-0109-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

New perspectives on effector mechanisms in uveitis

In vivo imaging of the immune response in the eye

Immunopathological aspects of age-related macular degeneration

Autoimmune retinopathy: A review and summary

Mechanisms of leukocyte migration across the blood–retina barrier

Immunopathology of the eye

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials